Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A.

J Immunother Cancer. 2019 Jun 24;7(1):158. doi: 10.1186/s40425-019-0639-4.

2.

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A.

Ann Hematol. 2019 Jul;98(7):1611-1616. doi: 10.1007/s00277-019-03708-9. Epub 2019 May 15.

PMID:
31093708
3.

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A.

J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1. Erratum in: J Immunother Cancer. 2019 Jun 24;7(1):158.

4.

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A.

J Immunother Cancer. 2019 Jan 6;7(1):2. doi: 10.1186/s40425-018-0478-8.

5.

Renal complications of primary myelofibrosis.

Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A.

Leuk Lymphoma. 2019 Feb;60(2):507-510. doi: 10.1080/10428194.2018.1474525. Epub 2018 Jul 3. No abstract available.

PMID:
29966471
6.

Magnesium: An Overlooked Electrolyte.

Kala J, Abudayyeh A.

J Emerg Med. 2017 May;52(5):741-743. doi: 10.1016/j.jemermed.2017.01.011. Epub 2017 Feb 17.

PMID:
28222929
7.

Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.

Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12632. Epub 2016 Dec 28.

PMID:
27862740
8.

Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam.

Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH.

Int J Cancer. 2017 Jan 15;140(2):460-468. doi: 10.1002/ijc.30458. Epub 2016 Oct 18.

9.

Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):176-189. doi: 10.2215/CJN.06100616. Epub 2016 Sep 21. Review.

10.

Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Finkel KW, Cohen EP, Shirali A, Abudayyeh A; American Society of Nephrology Onco-Nephrology Forum.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2273-2279. Epub 2016 Aug 15.

11.

Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury.

Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A.

Bone Marrow Transplant. 2016 Oct;51(10):1301-1304. doi: 10.1038/bmt.2016.120. Epub 2016 May 9.

PMID:
27159179
12.

Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients.

Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K.

Am J Transplant. 2016 May;16(5):1492-502. doi: 10.1111/ajt.13635. Epub 2016 Mar 2.

13.

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?

Abudayyeh A, Truong LD, Beck LH Jr, Weber DM, Rezvani K, Abdelrahim M.

Clin Kidney J. 2015 Aug;8(4):440-4. doi: 10.1093/ckj/sfv036. Epub 2015 Jun 1.

14.

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib.

Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A.

BMC Nephrol. 2015 Aug 1;16:121. doi: 10.1186/s12882-015-0121-6.

15.

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.

Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, Abudayyeh A.

PLoS One. 2015 Jun 2;10(6):e0128308. doi: 10.1371/journal.pone.0128308. eCollection 2015.

16.

Nuclear receptor 4A (NR4A) family - orphans no more.

Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB.

J Steroid Biochem Mol Biol. 2016 Mar;157:48-60. doi: 10.1016/j.jsbmb.2015.04.016. Epub 2015 Apr 23.

17.

Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.

Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S.

J Biol Chem. 2014 Oct 3;289(40):27692-701. doi: 10.1074/jbc.M114.592576. Epub 2014 Aug 20.

18.

Onconephrology: the need and the emergence of a subspecialty in nephrology.

Abudayyeh AA, Lahoti A, Salahudeen AK.

Kidney Int. 2014 May;85(5):1002-4. doi: 10.1038/ki.2014.29. No abstract available.

19.

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.

Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R.

Invest New Drugs. 2012 Jun;30(3):853-61. doi: 10.1007/s10637-010-9622-0. Epub 2011 Jan 4.

PMID:
21197621
20.

Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.

Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M.

Invest New Drugs. 2011 Feb;29(1):41-51. doi: 10.1007/s10637-009-9331-8. Epub 2009 Oct 23.

PMID:
19851711
21.

Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells.

Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, Smith R 3rd, Safe S.

Int J Cancer. 2009 Oct 15;125(8):1965-74. doi: 10.1002/ijc.24530.

22.

The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.

Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S.

Mol Cancer Ther. 2009 May;8(5):1207-17. doi: 10.1158/1535-7163.MCT-08-1097. Epub 2009 May 12.

23.

Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.

Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S.

Carcinogenesis. 2009 Jul;30(7):1193-201. doi: 10.1093/carcin/bgp092. Epub 2009 Apr 30.

24.

Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.

Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M.

Mol Cancer Ther. 2009 Mar;8(3):533-42. doi: 10.1158/1535-7163.MCT-08-0405. Epub 2009 Mar 3.

25.

5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells.

Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A, Safe S.

Mol Cancer Ther. 2008 Jul;7(7):2109-20. doi: 10.1158/1535-7163.MCT-07-2311.

26.

RNAi and cancer: Implications and applications.

Abdelrahim M, Safe S, Baker C, Abudayyeh A.

J RNAi Gene Silencing. 2006 Feb 28;2(1):136-45.

Supplemental Content

Loading ...
Support Center